Landscape of TIGIT and PD-L1 co-expression in solid tumors

Using comprehensive genomic and immune profiling on discovery cohort of 24,186 solid tumors across 35 tumor types, this study confirmed that TIGIT expression is correlated with PD-L1 expression. Patients whose tumors express higher levels of TIGIT and PD-L1 via immunohistochemistry had improved overall survival. This study further highlights the potential use of immune profiling to develop new novel combination therapies and clinical trial design across solid tumors.